GLP-1 (7-36) acid (human, mouse, rat, porcine, bovine) (Synonyms: Glucagon-like Peptide 1 (7-36) acid) |
| カタログ番号GC92119 |
GLP-1 (7-36) acid (human, mouse, rat, porcine, bovine)はホルモンとGLP-1受容体（GLP-1 R）アゴニストGLP-1（7-36）アミドの誘導体である。
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Glucagon-like peptide 1 (GLP-1) (7-36) acid is a derivative of the hormone and GLP-1 receptor (GLP-1R) agonist GLP-1 (7-36) amide.1,2 It enhances insulin-induced phosphorylation of Akt in 3T3-L1 adipocytes when used at a concentration of 100 nM in the presence of a dipeptidyl peptidase 4 (DPP-4) inhibitor.2 GLP-1 (7-36) acid (150 ?g/kg) reduces plasma levels of total cholesterol, triglycerides, free fatty acids, LDL, insulin, and leptin, as well as adipose tissue weight, in a mouse model of obesity induced by a high-fat diet. It decreases blood glucose levels, food intake, and gastric emptying in non-obese and ob/ob mice when administered at a dose of 3 mg/kg.1
References:
[1]. Fang, X., Du, Z., Duan, C., et al.Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse modelLife Sci.270:118966(2021).
[2]. Zhang, F., Chen, Z., Wu, D., et al.Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese miceiScience24(12)103382(2021).
| Cas No. | SDF | ||
| 同義語 | Glucagon-like Peptide 1 (7-36) acid | ||
| Chemical Name | L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginine, monoacetate | ||
| Canonical SMILES | OC(CC[C@H](NC([C@@H](NC([C@H](CC1=CN(C=N1)[H])N[H])=O)C)=O)C(NCC(N[C@@]([H])([C@@H](C)O[H])C(N[C@H](C(N[C@@]([H])([C@@H](C)O[H])C(N[C@@H](CO[H])C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CO[H])C(N[C@@H](CO[H])C(N[C@@H](CC(C=C2)=CC=C2O[H])C(N[C@H](C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CCC(N[H])=O)C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN[H])C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@@H](CC3=CN([H])C4=C3C=CC=C4)C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CCCCN[H])C(NCC(N[C@@H](CCC/N=C(N)\N[H])C(O)=O)=O)=O)=O)=O)CC(C)C)=O)=O)C)=O)([H])[C@H](CC)C)=O)CC5=CC=CC=C5)=O)=O)=O)C)=O)C)=O)=O)=O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)CC6=CC=CC=C6)=O)=O)=O)=O.CC(O)=O | ||
| Formula | C149H225N39O46 ? C2H4O2 | M.Wt | 3358.7 |
| 溶解度 | DMSO: Sparingly soluble: 1-10 mg/ml,PBS (pH 7.2): Slightly soluble: 0.1-1 mg/ml | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2977 mL | 1.4887 mL | 2.9773 mL |
| 5 mM | 0.0595 mL | 0.2977 mL | 0.5955 mL |
| 10 mM | 0.0298 mL | 0.1489 mL | 0.2977 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *